SAMHD1 Phosphorylation Coordinates the Anti-HIV-1 Response by Diverse Interferons and Tyrosine Kinase Inhibition. by Szaniawski, Matthew A et al.
Himmelfarb Health Sciences Library, The George Washington University
Health Sciences Research Commons
Microbiology, Immunology, and Tropical Medicine
Faculty Publications Microbiology, Immunology, and Tropical Medicine
5-15-2018
SAMHD1 Phosphorylation Coordinates the Anti-
HIV-1 Response by Diverse Interferons and
Tyrosine Kinase Inhibition.
Matthew A Szaniawski
Adam M Spivak
James E Cox
Jonathan L Catrow
Timothy Hanley
See next page for additional authors
Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/smhs_microbio_facpubs
Part of the Medical Immunology Commons, Medical Microbiology Commons, and the Tropical
Medicine Commons
This Journal Article is brought to you for free and open access by the Microbiology, Immunology, and Tropical Medicine at Health Sciences Research
Commons. It has been accepted for inclusion in Microbiology, Immunology, and Tropical Medicine Faculty Publications by an authorized
administrator of Health Sciences Research Commons. For more information, please contact hsrc@gwu.edu.
APA Citation
Szaniawski, M., Spivak, A., Cox, J., Catrow, J., Hanley, T., Williams, E., Tremblay, M., Bosque, A., & Planelles, V. (2018). SAMHD1
Phosphorylation Coordinates the Anti-HIV-1 Response by Diverse Interferons and Tyrosine Kinase Inhibition.. MBio, 9 (3).
http://dx.doi.org/10.1128/mBio.00819-18
Authors
Matthew A Szaniawski, Adam M Spivak, James E Cox, Jonathan L Catrow, Timothy Hanley, Elizabeth S C P
Williams, Michel J Tremblay, Alberto Bosque, and Vicente Planelles
This journal article is available at Health Sciences Research Commons: https://hsrc.himmelfarb.gwu.edu/smhs_microbio_facpubs/
332
SAMHD1 Phosphorylation Coordinates the Anti-HIV-1
Response by Diverse Interferons and Tyrosine Kinase
Inhibition
Matthew A. Szaniawski,a Adam M. Spivak,b James E. Cox,c Jonathan L. Catrow,c Timothy Hanley,a
Elizabeth S. C. P. Williams,a Michel J. Tremblay,d,e Alberto Bosque,f Vicente Planellesa
aDivision of Microbiology and Immunology, Department of Pathology, University of Utah School of Medicine,
Salt Lake City, Utah, USA
bDepartment of Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA
cDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, Utah, USA
dAxe des Maladies Infectieuses et Immunitaires, CR-CHU de Québec-Université Laval, Quebec City, QC, Canada
eDépartement de Microbiologie, Infectiologie et Immunologie, Université Laval, Quebec City, QC, Canada
fDepartment of Microbiology, Immunology, and Tropical Medicine, George Washington University,
Washington, DC, USA
ABSTRACT Macrophages are susceptible to human immunodeficiency virus type 1
(HIV-1) infection despite abundant expression of antiviral proteins. Perhaps the most
important antiviral protein is the restriction factor sterile alpha motif domain and
histidine/aspartic acid domain-containing protein 1 (SAMHD1). We investigated the
role of SAMHD1 and its phospho-dependent regulation in the context of HIV-1 infec-
tion in primary human monocyte-derived macrophages and the ability of various in-
terferons (IFNs) and pharmacologic agents to modulate SAMHD1. Here we show that
stimulation by type I, type II, and to a lesser degree, type III interferons share activa-
tion of SAMHD1 via dephosphorylation at threonine-592 as a consequence of signal-
ing. Cyclin-dependent kinase 1 (CDK1), a known effector kinase for SAMHD1, was
downregulated at the protein level by all IFN types tested. Pharmacologic inhibition
or small interfering RNA (siRNA)-mediated knockdown of CDK1 phenocopied the ef-
fects of IFN on SAMHD1. A panel of FDA-approved tyrosine kinase inhibitors po-
tently induced activation of SAMHD1 and subsequent HIV-1 inhibition. The viral re-
striction imposed via IFNs or dasatinib could be overcome through depletion of
SAMHD1, indicating that their effects are exerted primarily through this pathway.
Our results demonstrate that SAMHD1 activation, but not transcriptional upregula-
tion or protein induction, is the predominant mechanism of HIV-1 restriction in-
duced by type I, type II, and type III IFN signaling in macrophages. Furthermore,
SAMHD1 activation presents a pharmacologically actionable target through which
HIV-1 infection can be subverted.
IMPORTANCE Our experimental results demonstrate that SAMHD1 dephosphoryla-
tion at threonine-592 represents a central mechanism of HIV-1 restriction that is
common to the three known families of IFNs. While IFN types I and II were potent
inhibitors of HIV-1, type III IFN showed modest to undetectable activity. Regulation
of SAMHD1 by IFNs involved changes in phosphorylation status but not in protein
levels. Phosphorylation of SAMHD1 in macrophages occurred at least in part via
CDK1. Tyrosine kinase inhibitors similarly induced SAMHD1 dephosphorylation, which
protects macrophages from HIV-1 in a SAMHD1-dependent manner. SAMHD1 is a critical
restriction factor regulating HIV-1 infection of macrophages.
KEYWORDS CDK1, dasatinib, interferon, human immunodeficiency virus,
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Macrophages are major targets of human immunodeficiency virus type 1 (HIV-1),and their importance in infection establishment, progression, and persistence has
been studied at length (1, 2). They are thought to contribute importantly to virus
amplification and dissemination during primary infection, and in the central nervous
system (CNS), HIV-1-infected macrophages and microglia precipitate a spectrum of
neurological impairments that can persist in the setting of antiretroviral therapy (ART)
(3–5). It is known that macrophages exhibit low permissiveness to infection, in part due
to the constitutive expression of the antiviral restriction factor sterile alpha motif (SAM)
domain- and histidine/aspartic acid (HD) domain-containing protein 1 (SAMHD1), a
deoxynucleoside triphosphate (dNTP) triphosphohydrolase that restricts HIV-1 by main-
taining dNTP concentrations below the threshold required for efficient reverse tran-
scription (6–9).
Interferons (IFNs) play an important role in preventing viral infection through
multiple effector mechanisms. Numerous studies have pointed to enhanced expression
of various restriction factors that act at multiple stages of HIV-1 infection, including
MX2, GBP5, APOBEC3A, and others, to explain the potent antiviral effects of IFNs
(10–14). In this context, activation of the interferon regulatory factor (IRF) family of
transcription factors, nuclear translocation, and recognition of a conserved DNA se-
quence known as an IFN-stimulated response element (ISRE) present in the promoter-
enhancer regions of a number of genes direct these antiviral programs (15, 16). Though
alpha interferon (IFN-) and IFN- are perhaps the most well-studied type I IFNs,
numerous others exist in humans including IFN-, whose relevance in HIV-1 restriction
has been demonstrated recently in macrophages (17). The sole member of the type II
IFN family, IFN-, is widely recognized for its role in macrophage activation, and it was
recently shown to induce a potent, Env-dependent block to HIV-1 infection in CD4 T
cells that was distinct from that induced by type I IFN (18). The type III IFNs, which
include IFN-1, -2, and -3, have been shown to exhibit anti-HIV-1 activity, and may
be relevant in specific tissue sites such as the vaginal mucosa (19). Macrophages are
highly responsive to the modulating effects of many diverse interferons and interferon-
like molecules; however, the mechanisms underlying the potent anti-HIV-1 capacities of
diverse IFNs remain incompletely defined (20). SAMHD1 is regulated at the level of
phosphorylation by type I interferon, but to what extent type II and III IFNs affect
SAMHD1 phosphorylation and whether SAMHD1 is required for their activity remain
unknown (21).
In this study, we examined the abilities of divergent IFN families to inhibit HIV-1
infection in primary human monocyte-derived macrophages (MDM) and provide mech-
anistic insight into the major effector function of type I, type II, and type III IFNs. We
extended the study to explore the HIV-1 restriction potential of a panel of FDA-
approved tyrosine kinase inhibitors (TKI) in an effort to define SAMHD1 as a potential
pharmacologic target for anti-HIV-1 efforts. These studies show that SAMHD1 serves as
the key regulator of HIV-1 infectivity in MDM whose activity is rapidly induced at the
level of protein dephosphorylation.
RESULTS
Type I, type II, and type III IFNs induce SAMHD1-T592 dephosphorylation,
resulting in enhanced restriction of HIV-1 infection in MDM. We sought to deter-
mine whether IFNs from various families could differentially modulate SAMHD1 protein
levels or activity and whether these changes would in turn affect HIV-1 infection in
macrophages. CD14 monocytes were isolated from peripheral blood mononuclear
cells (PBMC) from healthy donors and MDM were generated following 7-day differen-
tiation. MDM were exposed for 24 h to 50-ng/ml concentrations of IFN-, IFN-, IFN-,
or IFN-. Macrophages were infected with a replication-competent R5-tropic recombi-
nant virus (HIV-1-BAL-HSA; see Fig. S1A in the supplemental material) (22) and analyzed
for CD24 (mHSA, mouse heat-stable antigen) expression by flow cytometry 48 h later
(Fig. 1A). Without IFN treatment, infection levels ranged between 1 and 16% among
donors. Because of the high degree of variability in infectivity among donors, we set
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FIG 1 Diverse IFNs restrict HIV-1 in MDM and induce SAMHD1 dephosphorylation. (A and B) Flow cytometric analysis of MDM
infected with replication-competent HIV-1-BAL-HAS (A) and HIV-1ΔEnv-GFP/VSVG (B). The numbers in each graph in the top panel
indicate the percentage of events falling within the CD24-positive gate. FSC, forward scatter; APC, allophycocyanin. Data from
multiple donors are summarized in the corresponding graph in the bottom panel, with each symbol representing the value for a
single donor and mean values from multiple donors provided as a percentage above each condition. Values that are significantly
different are indicated by bars and asterisks as follows: **, P  0.01; ***, P  0.001; ****, P  0.0001. Independent one-sample t tests
were used to determine significance between each IFN treatment condition to the no-IFN control. (C) Lysates (10 g) from MDM
from representative donors (A031 and A049) were analyzed by Western blotting for pSAMHD1-T592, total SAMHD1, and -actin.
Values below each lane indicate the ratio of pSAMHD1 to total SAMHD1 as determined by densitometry. (D) Correlation between
pSAMHD1-T592 and percent GFP-positive or (E) total SAMHD1 and percent GFP-positive MDM for donor A031 (circles) and donor
A049 (squares). Each symbol represents the mean percentage of infection from triplicate wells as measured by flow cytometry
plotted against the ratios determined by Western blotting densitometry, as calculated in Fig. 1C.
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infection levels in the absence of IFN to 100% for each individual donor and then
normalized infection in the presence of IFN to that value (Fig. 1A). In each case, IFN
treatment restricted infection, albeit to different degrees: IFN-, IFN-, and IFN-
potently suppressed infectivity. In contrast, IFN- reduced infectivity modestly and in a
highly variable manner, a degree of protection that could not be enhanced by
increasing concentrations of IFN- (Fig. S2A).
To determine whether the effects of IFN are specific to the nature of the envelope
glycoprotein, we utilized a replication-defective virus pseudotyped with vesicular sto-
matitis virus glycoprotein (VSVG) (HIV-1ΔEnv-GFP/VSVG [GFP stands for green fluores-
cent protein]; Fig. S1B). VSVG binds to the low-density lipoprotein receptor (LDL-R) for
entry and shunts the virus toward the endocytic pathway, bypassing membrane fusion
resulting from gp160 interaction with chemokine (C-C motif) receptor 5 (CCR5) (23).
HIV-1ΔEnv-GFP/VSVG was sensitive to each IFN tested, with IFN- exhibiting the least
potency and highest donor-to-donor variability. Therefore, we conclude that the ob-
served IFN-stimulated protection was induced against two viruses using distinct enve-
lope glycoproteins (HIV-1 gp160 versus VSVG) that recognize the corresponding recep-
tors (CD4 and CCR5 versus LDL-R) (Fig. 1B).
To examine the potential role of SAMHD1 in restriction by the various IFN types, we
generated cell lysates from MDM treated with IFN for 24 h and probed for total
SAMHD1 and pSAMHD1-T592 (phosphorylated SAMHD1 [T592 phosphorylated])
(Fig. 1C; two representative donors shown). Addition of recombinant IFN-, IFN-, or
IFN- led to a reduction in SAMHD1 phosphorylation that correlated directly with
reduced infectivity by HIV-1ΔEnv-GFP/VSVG (Fig. 1D). The levels of total SAMHD1
protein were not dramatically affected by any of the IFNs tested, and there was no
correlation between total SAMHD1 protein and infectivity after IFN stimulation (Fig. 1E).
SAMHD1 activation through T592 dephosphorylation is thus a conserved effector
mechanism resulting from stimulation of MDM by different IFN types.
SAMHD1 is active at baseline and controls MDM resistance to HIV-1. We
hypothesized that highly permissive MDM would exhibit a higher degree of SAMHD1
phosphorylation relative to the levels of total SAMHD1 protein. We derived MDM from
six healthy donors and exposed them to HIV-1ΔEnv-GFP/VSVG. In the absence of
stimulation, MDM from these donors exhibited vastly different levels of SAMHD1
phosphorylation (Fig. 2A) at baseline, which correlated directly with the levels of
infectivity (P  0.045; R2  0.6748; Fig. 2B). Infectivity did not correlate with the levels
of total SAMHD1 protein (Fig. 2C). Although a modest correlation between CCR5 cell
surface expression and infectivity was observed, differences in infectivity at baseline
cannot be attributed to variations in CD4 or CCR5 because the virus used in these
experiments was pseudotyped with VSVG (Fig. S2B and C). The finding that MDM from
healthy donors exhibit diverse phosphorylation levels of SAMHD1 that correlate directly
with infectivity supports our model in which infectivity in MDM depends on SAMHD1
activity and not expression.
SAMHD1 phosphorylation status is sufficient to explain IFN-induced HIV-1
restriction in primary MDM. To evaluate whether SAMHD1 is the relevant antiviral
effector responsible for the HIV-1 restriction induced by IFNs, we delivered the simian
immunodeficiency virus SIVmac accessory protein Vpx to ectopically induce SAMHD1
degradation (6–8, 24–26). To this end, we generated VSVG-pseudotyped virus-like
particles (VLP) containing the SIVmac accessory protein Vpx [Vpx()VLP] and, as a
control, VLP lacking Vpx [Vpx()VLP] (8, 24).
Cells were exposed to Vpx()VLP or Vpx()VLP for 6 h and treated for 18 h with
IFN. Cells were then infected with HIV-1ΔEnv-GFP/VSVG. SAMHD1 degradation by
Vpx()VLP and Vpx()VLP was evaluated by Western blotting 24 h after VLP addition,
and infection levels were evaluated by flow cytometry 48 h postinfection. Vpx()VLP
led to efficient SAMHD1 degradation and reversed the block to infection with HIV-
1ΔEnv-GFP/VSVG, while Vpx()VLP failed to do so (Fig. 3A and B, one representative
donor; additional donors shown in Fig. 3D). Importantly, reversal of the IFN-induced
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restriction in the presence of Vpx()VLP was independent of the amount of virus
utilized (Fig. S3A). Dephosphorylation of SAMHD1 for one representative donor from
this experiment is shown in Fig. 3C. Cells in the absence of IFN also demonstrated
increased infectivity when treated with Vpx()VLP. These results are consistent with
previous reports showing that Vpx can overcome the restriction imposed by SAMHD1
at baseline and in the absence of exogenous IFN stimulation, supporting the notion
that SAMHD1 is at least partially active under unstimulated conditions (Fig. 3D) (24).
To determine whether SAMHD1 activation results in a state of HIV-1 restriction that
stems from limiting dNTP levels, we exposed cells to high concentrations of deoxy-
nucleosides (dNs) in the culture medium prior to infection. We predicted that exoge-
nous dN administration would phenocopy the effect of Vpx()VLP and reverse the
IFN-induced antiviral activity. Deoxyribonucleosides are cell membrane permeable
and are converted to dNTPs once inside the cell (6). Addition of dNs to the medium
enhanced infection in the absence of IFN and efficiently relieved the IFN-induced
restriction in IFN-treated cells (Fig. 3E [two representative donors shown]). These
results, together with those in Fig. 3A to D, establish SAMHD1 dephosphorylation as the
principal effector mechanism against HIV-1 in the response of MDM to type I, II, and III
IFN, which results in dNTP depletion and impaired HIV-1 reverse transcription.
Canonical HIV-1 restriction factors, but not SAMHD1, are transcriptionally
induced by type I, type II, and type III IFN stimulation. To further explore and
compare the cellular responses to type I, II, and III IFN, we performed high-throughput
RNA sequencing (RNA-seq) with MDM stimulated with IFN-, IFN-, IFN-, or IFN-.
mRNA was isolated 18 h after stimulation and subjected to RNA-seq. Figure 4 shows the
log2 fold change (sequence reads in IFN treatment over those without IFN) in mRNA for
SAMHD1 along with a small subset of known interferon-stimulated genes (ISGs) (ISG15,
ABOBEC3A, SIGLEC-1, MX1, MX2, and OAS1), cell cycle regulators known to act on
SAMHD1 (cyclin-dependent kinase 1 [CDK1], -2, -4, and -6) and immune-related genes
(CD4, CCR5, chemokine [C-X-C motif] receptor 1 [CXCR1], and CD180). SAMHD1 mRNA
FIG 2 Macrophages exhibit diverse pSAMHD1-T592 signatures at baseline that correlate with infectivity. (A) Lysates of MDM from six
donors were analyzed by Western blotting for pSAMHD1-T592, total SAMHD1, and actin. Numbers indicate the proportion of pSAMHD1-
T592 to total SAMHD1 as calculated by Western blotting densitometry. Lanes were cut following development of a single membrane to
remove alternating lanes. (B) Correlation between pSAMHD1-T592 and the percentage of GFP-positive macrophages as analyzed by flow
cytometry. (C) Correlation between total SAMHD1 and the percentage of GFP-positive MDM. Linear regression analyses were performed
to study the relationships between infectivity, total SAMHD1 levels, and pSAMHD1 levels.
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FIG 3 SAMHD1 is the major downstream effector of diverse IFN types. (A) Representative Western blot analysis of MDM extracts not treated with
VLP or treated with Vpx()VLP and Vpx()VLP and probed for pSAMHD1-T592, total SAMHD1, and -actin. (B) Representative flow cytometric
analysis of viable MDM infected with a replication-incompetent HIV-1ΔEnv-GFP/VSVG in the presence or absence of 50 ng/ml IFN-, IFN-, IFN-,
or IFN- (rows) and treated with the Vpx VLP indicated (columns). Numbers in the graphs indicate the percentage of events falling within the
GFP-positive gate as established with mock-infected MDM. (C) Western blot analysis of pSAMHD1-T592, total SAMHD1, and actin for macrophages
from donor A051. (D) Bar graphs showing macrophages from three additional, independent donors with each condition conducted in triplicate. (E)
Macrophages from donors A006 and A026 were treated with IFN, exposed to 10 mM dN (), and then infected with HIV-1ΔEnv-GFP/VSVG. Bars
indicate the percent GFP-positive cells within the viable population as measured by flow cytometry.
Szaniawski et al. ®
May/June 2018 Volume 9 Issue 3 e00819-18 mbio.asm.org 6
 
m
bio.asm
.org
 o
n
 M
ay 31, 2018 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
levels were not dramatically affected by any of the IFN treatments (1.08-fold [IFN-],
1.24-fold [IFN-], 1.27-fold [IFN-], and 1.21-fold [IFN-]), in agreement with previous
reports in CD4 T cells and dendritic cells (27). In contrast, many ISGs were strongly
induced by each of the IFNs, exhibiting expression levels that ranged between
5-fold (ISG15 by IFN-) and 750-fold (APOBEC3A by IFN-) over the no-IFN condition
(Fig. 4A to D).
Among the cyclin-dependent kinases examined in our RNA-seq experiment, CDK1
mRNA was decreased 5.7-fold, 3.9-fold, and 20.8-fold after IFN-, IFN-, and IFN-,
respectively (Fig. 4A to C). CDK1 transcripts were modestly upregulated by IFN-
(1.4-fold), the only IFN with modest to undetected HIV-1 restriction in our studies.
Therefore, we speculated that downregulation of CDK1 by IFN-, IFN-, and IFN- is
part of the mechanism by which these IFNs induce dephosphorylation of SAMHD1. To
verify this prediction, we tested the CDK1/CDK2 inhibitor BMS-265246 for its ability to
restrict HIV-1ΔEnv-GFP/VSVG infection. BMS-265246 restricted HIV-1 infection in MDM,
whereas GW2580, a tyrosine kinase inhibitor (TKI) that targets colony-stimulating factor
1 receptor (CSF-1R) among other receptor tyrosine kinases (RTK), had no effect on viral
infectivity (Fig. 5A) (28).
We next used a small interfering RNA (siRNA) to CDK1 to verify its role in SAMHD1
phosphorylation and HIV-1 restriction. Knockdown of CDK1 resulted in a significant
reduction in SAMHD1 phosphorylation, concomitant with a reduction in MDM suscep-
tibility to HIV-1, while the use of a siRNA targeting SAMHD1 led to an enhanced
susceptibility of MDM to HIV-1 (Fig. 5B and C). In agreement with our findings with
Vpx()VLP, siRNA-mediated knockdown of SAMHD1 similarly reversed the IFN-induced
restriction to HIV-1, suggesting that the majority of the antiviral effect is exerted
through SAMHD1 activation (Fig. 5D).
SAMHD1 activity can be regulated pharmacologically. Because activation of
SAMHD1 imposes a potent blockade against HIV-1, it would be ideal if the activity
of SAMHD1 could be controlled pharmacologically. Recently, it was shown that this can
FIG 4 SAMHD1 is not a canonical ISG in MDM. (A to D). Gene expression signatures of select genes represented as log2
fold change relative to the untreated condition (no IFN) for IFN-, IFN-, IFN-, and IFN-.
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be accomplished in CD4 T cells with the use of dasatinib, a Bcr-Abl-specific TKI that
has been approved for use in chronic myelogenous leukemia (CML) and Philadelphia
chromosome-positive acute lymphoblastic leukemia (Ph AML) by the FDA (29, 30). We
tested a panel of tyrosine kinase inhibitors to determine whether they possess anti-
HIV-1 activity and whether that activity stems from SAMHD1 dephosphorylation.
Among the TKIs tested were dasatinib, bosutinib, crenolanib, palbociclib, and ponatinib.
FIG 5 siRNA to CDK1 and SAMHD1 reveal central roles in IFN-induced HIV-1 restriction. (A) The effect of CDK1/2 inhibition on infection with HIV-1ΔEnv-GFP/
VSVG was determined by flow cytometry, with infection in untreated cells set at 100%. Data on cells from three representative donors are shown. (B) Western
blot analysis of siRNA-treated MDM from donor A069. (C) Representative siRNA flow cytometry plots from two donors, donors A069 and A070. (D)
Representative flow cytometry plots from IFN-treated MDM with and without SAMHD1 knockdown.
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These compounds exhibit low cytotoxicity, are FDA approved, and target a variety of
cellular pathways, including Abl kinase, Src family kinases, type III RTK, as well as CDK4
and CDK6 (31). Each inhibitor led to HIV-1 restriction, with dasatinib providing the most
potent HIV-1 blockade (Fig. 6A). HIV-1ΔEnv-GFP/VSVG infectivity was inversely corre-
lated with the proportion of SAMHD1 present in its activated, dephosphorylated state
as manipulated by the TKIs (Fig. 6B and C). We focused on dasatinib to test whether
SAMHD1 phosphorylation and infectivity exhibited a dose-dependent relationship and
observed overt changes in pSAMHD1-T592 that corresponded to increasing concen-
trations of the inhibitor (Fig. 6B and C). The dephosphorylation of SAMHD1 was
concomitant with and inversely proportional to the infectivity by HIV-1ΔEnv-GFP/VSVG
(Fig. 6C).
TKIs, including dasatinib, target diverse cellular pathways at high nanomolar con-
centrations (32). If SAMHD1 is indeed responsible for the effects of the TKIs tested, then
incubation with Vpx()VLP following treatment should induce degradation of SAMHD1
and overcome the TKI-imposed restriction. Incubation with dasatinib rendered cells
highly resistant to infection (0.5%) compared with untreated cells (6.0%), representing
a 92% protection (Fig. 6D). Addition of Vpx()VLP to untreated cells enhanced infection
8.8-fold (6.0% to 53.0%), while addition of Vpx()VLP in the context of dasatinib
enhanced infection 76-fold (0.5% to 38%), representing a reversal of the dasatinib-
induced antiviral state. Taken together, our experiments establish a causal link between
SAMHD1 activation and protection from HIV-1 infectivity in MDM and provide evidence
supporting a dynamic regulatory role for SAMHD1 in MDM. Furthermore, we demon-
strate that SAMHD1 activity can be manipulated pharmacologically to render macro-
phages refractory to HIV-1 infection.
FIG 6 SAMHD1 is required for TKI-induced restriction. (A) Summary flow cytometric analysis of HIV-1 infection in four separate donors
treated with various TKIs. The TKIs were dasatinib (DAS), crenolanib (CRE), bosutinib (BOS), palbociclib (PAL), and ponatinib (PON). Values
indicate the percent GFP-positive cells within the viable population of cells infected with HIV-1ΔEnv-GFP/VSVG. The viability of TKI-treated
cells is between 90 and 100% that of untreated cells (No Tx). (B) Western blot analysis of lysates of MDM from two representative donors
treated with the indicated concentration of dasatinib. (C) Correlation between relative pSAMHD1-T592 and infectivity for macrophages
from six donors treated with 0 nM, 50 nM, and 100 nM dasatinib. (D) MDM treated with 500 nM dasatinib and treated with the Vpx VLP
indicated. Numbers represent the percentage of live cells within the GFP-positive gate as established with mock-infected MDM. Linear
regression analysis was performed to study the relationship between infectivity and pSAMHD1 levels during dasatinib treatment.
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DISCUSSION
Our experiments demonstrate that SAMHD1 dephosphorylation at threonine-592
represents a central mechanism of HIV-1 restriction that is common to the three known
families of IFNs, though with vastly different efficiencies, as evidenced by the limited
potency of IFN-. Enhanced dNTPase activity appears to be the functional outcome of
SAMHD1 activation, supported by several lines of evidence, including complete reversal
of the IFN-induced restriction by the addition of exogenous dNs and degradation of
SAMHD1 by the SIV protein Vpx (8, 24). The finding that diverse IFNs are functional to
the degree to which they modulate SAMHD1 phosphorylation and activation without
effecting changes in total protein is an important step in understanding innate immune
responses in macrophages. We also clarify that the previously reported antiviral activity
of IFN- is associated with dephosphorylation of SAMHD1 similar to what has been
described for other type I IFNs (17). Finally, we show that HIV-1 inhibition by various
FDA-approved TKIs is dependent on the activation of SAMHD1, providing important
mechanistic understanding as to how these compounds act and can be directed
toward HIV-1 cure efforts.
Macrophages are important targets of HIV-1 infection in vivo and are key players in
infection establishment and viral persistence (33, 34). It has been speculated that
macrophages can support HIV-1 infection and harbor virus over prolonged periods of
time independent of T cells, even in the setting of ART, a hypothesis that has recently
been strengthened by experiments conducted in humanized myeloid-only mice (1, 35).
Therefore, strategies that aim to prevent virus spread to tissue macrophages, either
independently or in the context of latency reversal, will be important components of
ongoing HIV-1 cure efforts.
SAMHD1 was first identified as the human homolog of a previously described mouse
IFN--inducible GTP-binding protein known as MG11 (36, 37). Recently, SAMHD1 has
been shown to be induced by stimulation with type I and type II IFNs via downregu-
lation of miR-181 and miR-30a in human monocytes (38). A similar phenomenon was
observed in astrocytes and microglia and was also dependent on miR181a (39). In
hepatocytes, it has been shown that type I and type II IFN can induce SAMHD1
transcription, inducing an antiviral state that restricts hepatitis B virus (HBV) infection
(40). Additionally, it has been shown that in mature dendritic cells (DCs), coculture with
lymphocytes can lead to downregulation of SAMHD1 and enhance DC permissiveness
to HIV-1 (41). In the present study, we show that the type I, II, and III IFN-induced HIV-1
restriction in MDM is not derived from changes in SAMHD1 protein or mRNA levels and
that the antiviral state hinges upon changes in SAMHD1 activity as determined by T592
phosphorylation.
The activity of SAMHD1 in lymphocytes is regulated by cyclin/cyclin-dependent
kinase (CDK)-mediated threonine-592 phosphorylation in a cell cycle-dependent man-
ner (21). However, SAMHD1 phosphorylation can also be regulated independent of cell
division (42). The specific CDKs responsible for SAMHD1 kinase activity depend on cell
type, with CDK1, CDK2, CDK4, and CDK6 all demonstrating a regulatory effect on
SAMHD1 in different contexts (21, 42–44). Phosphorylation of residue T592 impairs
SAMHD1 tetramerization resulting in diminished capacity for dNTP hydrolysis and
impaired anti-HIV-1 activity (45, 46). Our results suggest that IFN-induced activation of
SAMHD1 is effected via downregulation of CDK1 mRNA and indicate that in the
absence of stimulation, CDK1 maintains SAMHD1 phosphorylated and, to a large
extent, inactive. However, CDK1 cannot be the sole regulator of SAMHD1 in MDM, as
we also observed a modest downregulation of CDK1 protein by IFN-, which was not
accompanied by significant protection from viral infection. Therefore, additional fac-
tors, such as phosphorylation of CDK1, or the action of an IFN-regulated phosphatase,
need to be identified.
The finding that diverse IFNs converge on SAMHD1 activation reveals a common
denominator in IFN signaling, despite differences in expression of numerous other
documented antiviral genes in response to IFN stimulation (10–13). Whether restriction
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factors other than SAMHD1 were at play in our studies is unclear, though plausible. In
fact, a recent study showed that SIV Vpx of red-capped mangabeys and mandrills
(SIVrcm/mnd-2) enhances HIV-1 infection specifically in resting CD4 T cells in a
SAMHD1- and dNTP pool-independent manner and led the authors to suggest the
existence of an unknown restriction factor (47).
Importantly, the present study utilized two major virus clones, both of which are
derived from the lab-adapted, NL4-3 infectious clone (48). It is known that viruses
present during the acute phase of infection, termed transmitted-founder (T/F) viruses,
exhibit enhanced resistance to type I IFN than those present during chronic infection
(chronic carrier [C/C]) (49, 50). HIV-1-BAL-HSA, a hybrid virus composed of HIV-1-BAL
envelope expressed on a lab-adapted NL4-3 background, showed a trend in IFN
susceptibility similar to those observed with our NL4-3-derived HIV-1ΔEnv-GFP/VSVG
construct (22). Future studies aimed at delineating the requirement of SAMHD1 acti-
vation for diverse IFN function in the setting of T/F and C/C HIV-1 strains will be
important in further understanding the biology of infection of macrophages with HIV-1,
specifically with respect to those IFNs expressed in mucosal sites of transmission
(51, 52).
SAMHD1 has recently been proposed as a potential tumor suppressor, and in
fact, many FDA-approved anti-cancer TKIs have potent effects on SAMHD1 activa-
tion in vitro and in vivo (29, 30, 44). In cancer, SAMHD1 is thought to play a role in
controlling cell cycle of tumor cells, where its activity as a triphosphohydrolase can
restrain uncontrolled cellular proliferation by blunting cellular DNA synthesis (53,
54). Expanding our study beyond the natural biology of HIV-1 infection, we show
that SAMHD1 activity can be targeted by several FDA-approved anti-cancer TKIs.
TKIs exerted their anti-HIV-1 activity through threonine (T592) dephosphorylation,
which is unusual. We speculate that TKIs inhibit a signaling cascade initiated by TK
culminating in the regulation of Ser/Thr kinases, including CDK1. Future studies
aimed at delineating these pathways will be important in understanding how
SAMHD1 activity is controlled at steady state and can be manipulated therapeuti-
cally. Targeting the relevant pathways may prove useful in anti-HIV-1 efforts or in
preventing end organ damage observed in patients on ART, including HIV-1-
associated neurologic dysfunction.
MATERIALS AND METHODS
Isolation of healthy donor PBMC. Healthy donors 18 years old and older were recruited for this
study under the University of Utah Institutional Review Board (IRB) protocol 67637. Written informed
consent was obtained from all donors. Whole blood was obtained by peripheral phlebotomy, and
peripheral blood mononuclear cells (PBMC) were isolated using a Lymphoprep density gradient (Stemcell
Technologies).
Generation and infection of MDM. CD14 monocytes were isolated via positive selection with
magnetic beads (Miltenyi Biotec). Cells were allowed to adhere in serum-free medium for 2 h, which was
then removed and replaced with RPMI 1640 medium supplemented with 10% pooled human serum
(Innovative Research). The medium was changed at day 5, and cells were cultured for a total of 7 days
to allow differentiation to MDM prior to experimentation as previously described. MDM were infected
with 250 ng of either HIV-1-BAL-HSA or HIV-1ΔEnv-GFP/VSVG as determined by p24 enzyme-linked
immunosorbent assay (ELISA) for 6 h. Cells were washed twice with fresh medium to remove unbound
virus. Infection was quantified via flow cytometry at 48 h postinfection.
Generation of viruses. Replication-defective virus (HIV-1ΔEnv-GFP/VSVG) was generated using
calcium phosphate-mediated transfection of HEK293T cells. Briefly, HIV-1ΔEnv-GFP and VSVG plasmids
were cotransfected for 6 h. The transfection medium was removed, and cells were cultured over 2 days,
with virus-containing supernatants removed at 24 and 48 h posttransfection. These viruses contain a
frameshift mutation in envelope and are capable of only a single-round infection when Env is provided
in trans as previously described (55). Replication-competent virus (HIV-1-BAL-HSA) was generated
through a similar transfection protocol using a single plasmid (pNL-43-BAL-IRES-HSA) courtesy of Michel
Tremblay (Centre Hospitalier de l’Université Laval). All viruses were quantified using p24 ELISA (Zep-
tometrix) and stored at 80 °C until further use.
RNA-seq analysis for ISGs. MDM were generated as described and stimulated with 25 ng/ml of the
indicated IFNs. Total RNA was isolated 18 h following stimulation using RNeasy minikit (Qiagen). Intact
poly(A) RNA was purified from total RNA samples (100 to 500 ng) with oligo(dT) magnetic beads, and
stranded mRNA sequencing libraries were prepared as described using the Illumina TruSeq Stranded
mRNA Library Preparation kit (catalog no. RS-122-2101 and RS-122-2102). Purified libraries were qualified
on an Agilent Technologies 2200 TapeStation using a D1000 ScreenTape assay (catalog no. 5067-5582
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and 5067-5583). The molarity of adapter-modified molecules was defined by quantitative PCR using the
Kapa Biosystems Kapa Library Quant kit (catalog no. KK4824). Individual libraries were normalized to
10 nM, and equal volumes were pooled in preparation for Illumina sequence analysis. Sequencing
libraries (25 pM) were chemically denatured and applied to an Illumina HiSeq v4 single-read flow cell
using an Illumina cBot system. Hybridized molecules were clonally amplified and annealed to sequencing
primers with reagents from an Illumina HiSeq SR cluster kit v4-cBot (catalog no. GD-401-4001). Following
transfer of the flow cell to an Illumina HiSeq 2500 instrument (HCSv2.2.38 and RTA v1.18.61), a 50-cycle
single-read sequence run was performed using HiSeq SBS kit v4 sequencing reagents (catalog no.
FC-401-4002).
Inhibitors and IFNs. Recombinant human IFN- (PBL Assay Science), IFN- (EnQuire Bio), IFN-
(PeproTech), and IFN- (PeproTech) were purchased from suppliers, resuspended at 50 ng/l, and added
to cell culture at 50 ng/ml, the optimal concentration for HIV-1 restriction determined empirically in our
cell culture system. The following units of each IFN tested were used: 7,850 U/test for IFN-, 500 U/test
for IFN-, and 125 U/test for IFN-. IFN- specific activity was untested by the manufacturer and thus
utilized at a mass concentration identical to IFN-, IFN-, and IFN-. Inhibitors were purchased from
suppliers and resuspended at a concentration of 1 mM and added to culture at a concentration
of 1 M.
siRNA knockdown of CDK1 and SAMHD1. MDM were transfected twice (24 h apart) with either
control siRNA or siRNAs against SAMHD1 or CDK1 at a final concentration of 111 nM using Lipofectamine
RNAiMAX (Thermo Fisher) according to the manufacturer’s protocol. At 6 h posttransfection, cells were
supplemented with 1 volume of RPMI 1640 medium supplemented with 10% pooled human serum.
Twenty-four hours after the second transfection, the cells were either mock infected or infected with
HIV-1ΔEnv-GFP/VSVG. Forty-eight hours later, MDM were analyzed for green fluorescent protein (GFP)
expression via flow cytometry or lysed and analyzed via Western blotting and probed for SAMHD1,
pSAMHD1, and CDK1 expression.
Quantification of cellular deoxynucleoside triphosphates (dNTPs). Samples were extracted by
adding 90 l of an ice-cold 60% solution of methanol (aqueous) which contained 0.1 g/ml of 13C10-15N5
ATP (Sigma-Aldrich) as an internal standard. Each sample was vortexed for 10 s and chilled at20°C prior
to being centrifuged for 10 min at 20,000 relative centrifugal force (RCF) at 4°C. The supernatant was
removed to a fresh tube and dried overnight en vacuo. Immediately prior to liquid chromatography-mass
spectrometry (LC-MS) analysis, the samples were reconstituted in 50 l water containing 10 mM
ammonium carbonate.
Mass spectral analysis was performed using an Agilent 6490 ultraperformance liquid chromatography
(UPLC) triple-quadrupole (QQQ) MS system (Santa Clara, CA). A SeQuant ZIC hydrophilic interaction liquid
chromatographic (HILIC) column (Millipore Sigma, Burlington, MA) was used for fractionation using a
linear gradient of 10:90 acetonitrile (ACN)–10 mM ammonium acetate buffer to 20:80 ACN–10 mM
ammonium acetate buffer over 20 min at a flow rate of 0.2 ml/min. Mass spectrometry was performed
in the positive mode with an Agilent jet stream (AJS) electrospray ionization (ESI) source using tandem
mass spectrometry (MS/MS) fragmentation. The deoxynucleotides were positively identified by both
chromatographic retention time, and the ion ratios were identified by at least two selected reaction
monitoring (SRM) transitions. Quantitative data analysis was conducted using Agilent MassHunter Quant
software for dCTP using the internal standard to normalize signal between samples.
Statistical analysis. All statistical analyses were performed using GraphPad Prism 5.0 (GraphPad
Software, San Diego, CA).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
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